Slide 1: Stevanato Group Q4 and FY 2025 Financial Results
Stevanato Group Q4 and FY 2025 Financial Results March 4, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) a
Slide 3: Stevanato Group Q4 and FY 2025 Financial Results Earnings Call
Stevanato Group Q4 and FY 2025 Financial Results Earnings Call Franco Marco Lisa Stevanato Dal Lago Miles Chairman & CEO CFO CCO and IR Q4 and FY 2025 Financial Results 3
Slide 4: Franco Stevanato
x Franco Stevanato Chairman & Chief Executive Officer Q4 and FY 2025 Financial Results
Slide 5: FY25: Top-line Growth, Record Mix of HVS, and Continued Margin Expansion
FY25: Top-line Growth, Record Mix of HVS, and Continued Margin Expansion Ended 2025 With Another Solid Quarter Leading To Positive Full-Year Performance And Strong Momentum As We Start 2026 Continued Strong Growth from HVS • Total Company revenue increased 9% at constant currency (7% on a (Revenues
Slide 6: Injectable Biologics Remain Fastest Growing End-Market
Injectable Biologics Remain Fastest Growing End-Market Share of Revenues from Biologics Successful in Winning our fair Share of the GLP Market (Revenues from Biologics as a % of BDS Revenues) • Revenue from GLP1s accounted for approx. 19% to 20% of total Company revenue, growing 50%+ compared to 202
Slide 7: Demand-driven Capacity Expansion Projects to Support Growth in Biologics
Demand-driven Capacity Expansion Projects to Support Growth in Biologics Latina, Italy Fishers (IN), U.S. Diversifying EMEA footprint with expanding capacity Supporting U.S. customers across the full value chain, for PFS and EZ-fill® cartridges to satisfy market demand strategically focused to meet
Slide 8: Engineering Segment: Progress Update on Optimization Plan
Engineering Segment: Progress Update on Optimization Plan • Focused 2025 efforts on advancing the operations Optimization Plan (i) right-sizing operations, (ii) streamlining processes, (iii) increasing standardization, and (iv) strengthening internal functions (eg, Project Management Office) • Conso
Slide 9: Marco Dal Lago
x Marco Dal Lago Chief Financial Officer Q4 and FY 2025 Financial Results
Slide 10: Q4 2025: Financial Highlights
Q4 2025: Financial Highlights Q4 2025: Revenue Q4 2025: Margins (€ Million) HVS non-HVS growth at CC • Gross profit margin increased 120 bps to 30.9%, driven by: i. Favorable mix of accretive HVS +5% ii. Improvements from Latina and Fishers as we scale 331 346 production (sites remain margin-dilutiv
Slide 11: Q4 2025: Segment Trends
Q4 2025: Segment Trends Biopharmaceutical and Diagnostic Solutions (BDS) Segment +10% Revenue increased 10% (13% at cc), driven by growth in HVS REVENUE 307 • Record-level of HVS revenue of €171.4 M accounted for 56% of Segment revenue; 31% yoy 279 (€ Million) HVS growth underpinned primarily by str
Slide 12: Balance Sheet and Cash Flow Items
Balance Sheet and Cash Flow Items At Quarter Ended December 31, 2025 Cash and Cash Equivalents € 130.6 M Net Debt € 337.7 M In Fiscal Year 2025 CAPEX € 294.9 M • 89% of Capex tied to growth In Fiscal Year 2025 Cash from operating activities + € 286.1 M • Higher than anticipated FCF driven by (i) bet
Slide 13: FY 2026 Guidance
FY 2026 Guidance FY 2026 Guidance Implied Growth Revenue € 1.260B - € 1.290B 6% to 9% Revenue at Constant Currency € 1.278B - € 1.308B 8% to 10% Adjusted DEPS* € 0.59 - € 0.63 8% to 16% Adjusted EBITDA* € 331.8M - € 346.9M 11% to 16% FY 2026 Guidance assumes: • The second half of 2026 will be strong
Slide 14: Franco Stevanato
x Franco Stevanato Chairman & Chief Executive Officer Q4 and FY 2025 Financial Results
Slide 15: Remain Focused On Executing Our Key Priorities, Supported By Strong Business Fundamentals
Remain Focused On Executing Our Key Priorities, Supported By Strong Business Fundamentals • We operate in attractive, growing end markets with favorable secular tailwinds • Strong innovation advancing patient care (i) delivering novel biologics supporting new therapeutic areas, such as obesity, (ii)
Slide 16: Thank You
Upcoming Conferences and Marketing Activities • Bank of America Injectable Drug Package call series – March 9, 2026 (virtual) • KeyBanc Capital Markets Healthcare Forum – March 17, 2026 (virtual) Thank You Investor Relations Contacts Media Relations Contacts lisa.miles@stevanatogroup.com caterina.tr
Slide 17: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP f
Slide 18: Reconciliation of Non-GAAP Financial Measures (1/5)
Reconciliation of Non-GAAP Financial Measures (1/5) Reconciliation of Revenue to Constant Currency Revenue Reconciliation of EBITDA (Amounts in € millions) (Amounts in € millions) Biopharmaceutical For the three months For the years and Change Change ended December 31, ended December 31, Diagnostic
Slide 19: Reconciliation of Non-GAAP Financial Measures (2/5)
Reconciliation of Non-GAAP Financial Measures (2/5) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) Three months ended December 31, Operating Income Operating Income EBITDA Net Profit Diluted E
Slide 20: Reconciliation of Non-GAAP Financial Measures (3/5)
Reconciliation of Non-GAAP Financial Measures (3/5) Capital Employed (Amounts in € millions) As of As of December 31, December 31, 2025 2024 - Goodwill and Other intangible assets 86.8 83.6 - Right of Use assets 12.4 15.7 - Property, plant and equipment 1,391.5 1,248.4 - Financial assets - investmen
Slide 21: Reconciliation of Non-GAAP Financial Measures (4/5)
Reconciliation of Non-GAAP Financial Measures (4/5) CAPEX Net (Debt) / Net Cash (Amounts in € millions) (Amounts in € millions) As of As of For the three months For the year Change Change December 31, December 31, ended December 31, ended December 31, 2025 2024 2025 2024 € 2025 2024 € Non-current fi
Slide 22: Reconciliation of Non-GAAP Financial Measures (5/5)
Reconciliation of Non-GAAP Financial Measures (5/5) Reconciliation of 2026 Guidance* Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) Operating Revenue EBITDA Net Profit Diluted EPS Profit 1,260.0 - Reported 1,290.0 317.7 - 332.9